Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : HOX Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Hox Therapeutics and Vernalis Announce a Drug Discovery Collaboration in Oncology
Details : Through collaboration, Vernalis will get access to the Hit ID platforms to produce the target protein, and to identify and characterise small molecule inhibitors of the oncology target.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 20, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : HOX Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Pierre Fabre Laboratories and Vernalis Announce a Drug Discovery Collaboration in Oncology
Details : Under the terms of the collaboration, Vernalis will use its expertise to enable drug discovery against an undisclosed portfolio of multiple oncology targets and use fragment and structure-based methods to identify small molecules that modulate their acti...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 25, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Unison Medicines
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the agreement, Vernalis will use its expertise in drug discovery to design small molecules against this particularly challenging target, which has long been considered to be undruggable.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 09, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Unison Medicines
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The new 3 years research collaboration combines Vernalis’ strengths in structure and biophysics-based methods as part of the Vernalis Design Platform with the oncology expertise at Servier to enable to identify and enable new therapeutic targets.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 15, 2020